CITIUS PHARMACEUTICALS INC CTXR
ASignal's systematic analysis rates CTXR as Bearish.
Reflects the latest available analysis · analyzed Nov 14, 2026
The case on CTXR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram indicating strengthening momentum
- Debt-to-equity ratio of 0.09x indicates low leverage
- Gross margin of 77.34% suggests strong pricing power
- Cash position exceeds total debt
- Negative price momentum (-0.048)
- SMA50 above SMA20 suggesting downtrend
- Operating margin at -807.43% indicating severe losses
- Negative return on equity (-81.09%) and return on assets (-26.57%)
- Negative operating and free cash flow
- Current and quick ratios below 1.0 indicating liquidity risk
See the full verdict on CTXR
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CTXR
Most investors never get a second opinion, let alone several. ASignal runs CTXR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.